Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- (-) Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- (-) Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 81 Results
ICER’s UPI Report: Unsupported Policy Information
The 2023 iteration of ICER's Unsupported Price Increase report is misguided at best and harmful to patients and society at worst. NPC outlines why the report should not be used to determine policy or…
NPC’s John O’Brien Talks IRA, Drug Pricing, Patient Costs & Access on The Real Chemistry Podcast
In the latest episode of The Real Chemistry Podcast, NPC President and CEO John M. O'Brien spoke with Real Chemistry’s Founder and Chairman, Jim Weiss, on pressing health policy issues.
NPC Evaluates ICER’s Revised 2023 Value Assessment Framework: A Missed Opportunity for Patients and the Field
The Institute for Clinical and Economic Review (ICER) released its revised value assessment framework. NPC outlines key concerns about the framework and the impact on both patients and those who…
Health Spending Post-Pandemic: Looking for High Value Beyond the Headlines
NPC Chief Science Officer Dr. Sharon Phares takes a closer look at CMS' national health expenditure report and what their predictions mean for our health care system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and…
How the Myth of Average Persists in Health Benefits
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are…
NPC Submits Comments on Medicare Physician Fee Schedule Proposed Rule
NPC submitted comments on the Medicare Program’s CY 2022 Physician Fee Schedule proposed rule recommending opportunities to enhance understanding of patient-reported outcomes and address barriers to…
A Healthier Country Means Lower Health Care Spending
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…
Webcast: Priorities for Patient-Centered Care in Oncology
On a recent webcast, NPC Vice President of Health Services Research Kimberly Westrich discusses the importance of patient-centered care and the benefits and opportunities of incorporating…
Building a Better Evidence Base to Address the Social Determinants of Health
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how…
What the Data Are Saying on Drug Pricing and Utilization
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
NPC Shared Decision-Making and Value-Based Care Research Featured at PQA Annual Meeting
Research conducted by NPC and Discern Health found that shared decision-making and patient decision aid interventions do not always lead to reduced health care costs or utilization.
Patient Voices in Value-Based Cancer Care: Priorities for the Biden Administration
The key to elevating patient voices is using the right tools when developing a value-based payment model: patient-reported measures (PRMs), tools that capture patients’ voices related to their care…
Health Budgets Should Cap Patient Harm
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…